DelveInsight’s, “Severe Asthma Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Severe Asthma pipeline landscape. It covers the Severe Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Severe Asthma Treatment Landscape. Click here to read more @ Severe Asthma Pipeline Outlook

 

Key Takeaways from the Severe Asthma Pipeline Report

• In January 2025:- AstraZeneca:- This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.
• In January 2025: Upstream Bio Inc.:- The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
• In January 2025:- Incyte Corporation:- A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.
• DelveInsight’s Severe Asthma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
• The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
• Promising Severe Asthma Therapies such as Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.

 

Stay informed about the cutting-edge advancements in Severe Asthma treatments. Download for updates and be a part of the revolution in Respiratory Diseases care @ Severe Asthma Clinical Trials Assessment

 

Severe Asthma Emerging Drugs

 

• GSK3511294: GlaxoSmithKline

GSK 3511294, also known as depemokimab, is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by GlaxoSmithKline, for the treatment of asthma. GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of severe asthma.

 

• BSI-045B: Biosion

BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion’s collaboration partner – CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma.

 

• Mepolizumab: Bio-Thera Solutions

Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody administered subcutaneously via syringe or autoinjector. It is currently indicated for several conditions: as an add-on maintenance treatment for adult and pediatric patients aged six years and older with severe asthma characterized by an eosinophilic phenotype; as an add-on maintenance treatment for adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps; for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis; and for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome of at least six months’ duration without an identifiable non-hematologic secondary cause. Currently the drug is in Phase I stage of its clinical trial for the treatment of severe asthma.

 

Explore groundbreaking therapies and clinical trials in the Severe Asthma Pipeline. Access DelveInsight’s detailed report now! @ Severe Asthma Treatment Drugs

 

Severe Asthma Companies

Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.

 

Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Severe Asthma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Unveil the future of Severe Asthma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Severe Asthma Market Drivers and Barriers

 

Scope of the Severe Asthma Pipeline Report

• Coverage- Global
• Severe Asthma Companies- Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
• Severe Asthma Therapies- Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.
• Severe Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Severe Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Severe Asthma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Severe Asthma Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Severe Asthma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Severe Asthma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. GSK3511294: GlaxoSmithKline
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. BSI-045B: Biosion
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Mepolizumab: Bio-Thera Solutions
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Severe Asthma Key Companies
21. Severe Asthma Key Products
22. Severe Asthma- Unmet Needs
23. Severe Asthma- Market Drivers and Barriers
24. Severe Asthma- Future Perspectives and Conclusion
25. Severe Asthma Analyst Views
26. Severe Asthma Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dyspepsia-market